Cargando…

Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal

Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients’ quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid maligna...

Descripción completa

Detalles Bibliográficos
Autores principales: Araújo, António, Tavares, Nuno, Faria, Ana Luísa, Gomes, Rosa, Mendonça, Joana Carvalho, Parente, Bárbara, Capela, Andreia, Barata, Fernando, Macedo, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954894/
https://www.ncbi.nlm.nih.gov/pubmed/36826078
http://dx.doi.org/10.3390/curroncol30020117
_version_ 1784894225750425600
author Araújo, António
Tavares, Nuno
Faria, Ana Luísa
Gomes, Rosa
Mendonça, Joana Carvalho
Parente, Bárbara
Capela, Andreia
Barata, Fernando
Macedo, Ana
author_facet Araújo, António
Tavares, Nuno
Faria, Ana Luísa
Gomes, Rosa
Mendonça, Joana Carvalho
Parente, Bárbara
Capela, Andreia
Barata, Fernando
Macedo, Ana
author_sort Araújo, António
collection PubMed
description Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients’ quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid malignant tumours receiving Moderate or Highly Emetogenic Chemotherapy (MEC or HEC) in Portugal. During the study, patients completed three evaluations, and nausea severity and CINV impact on patients’ daily life was assessed. A complete response (no emetic episodes, no use of rescue antiemetic medication, and no more than mild nausea) was observed in 72% of the cycles (N = 161) throughout the five days after chemotherapy. Amongst the patient population, 25% classified their CINV episodes as severe. Though more than half of the patients achieved a complete response, suggesting that a therapeutic effort is being made to minimise this side effect, the overall scenario is barely optimistic. Significantly, new CINV-control measures in MEC/HEC patients should be adopted, specifically avoiding the single use of dexamethasone and 5-HT3 and raising awareness of using NK1-RAs. Thus, it is critical to improve CINV prophylactic treatment and implement practical international antiemetic guidelines in Portuguese clinical practice, envisaging the improvement of supportive care for cancer patients.
format Online
Article
Text
id pubmed-9954894
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99548942023-02-25 Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal Araújo, António Tavares, Nuno Faria, Ana Luísa Gomes, Rosa Mendonça, Joana Carvalho Parente, Bárbara Capela, Andreia Barata, Fernando Macedo, Ana Curr Oncol Article Chemotherapy-induced nausea and vomiting (CINV) negatively impact cancer patients’ quality of life and treatment outcomes. This study evaluated the achievement of complete response to CINV prophylaxis during the first five days after chemotherapy in adult outpatient cancer clinics with solid malignant tumours receiving Moderate or Highly Emetogenic Chemotherapy (MEC or HEC) in Portugal. During the study, patients completed three evaluations, and nausea severity and CINV impact on patients’ daily life was assessed. A complete response (no emetic episodes, no use of rescue antiemetic medication, and no more than mild nausea) was observed in 72% of the cycles (N = 161) throughout the five days after chemotherapy. Amongst the patient population, 25% classified their CINV episodes as severe. Though more than half of the patients achieved a complete response, suggesting that a therapeutic effort is being made to minimise this side effect, the overall scenario is barely optimistic. Significantly, new CINV-control measures in MEC/HEC patients should be adopted, specifically avoiding the single use of dexamethasone and 5-HT3 and raising awareness of using NK1-RAs. Thus, it is critical to improve CINV prophylactic treatment and implement practical international antiemetic guidelines in Portuguese clinical practice, envisaging the improvement of supportive care for cancer patients. MDPI 2023-01-24 /pmc/articles/PMC9954894/ /pubmed/36826078 http://dx.doi.org/10.3390/curroncol30020117 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Araújo, António
Tavares, Nuno
Faria, Ana Luísa
Gomes, Rosa
Mendonça, Joana Carvalho
Parente, Bárbara
Capela, Andreia
Barata, Fernando
Macedo, Ana
Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
title Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
title_full Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
title_fullStr Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
title_full_unstemmed Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
title_short Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
title_sort evaluation of current antiemetic therapy response in patients undergoing mec or hec regimens in portugal
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954894/
https://www.ncbi.nlm.nih.gov/pubmed/36826078
http://dx.doi.org/10.3390/curroncol30020117
work_keys_str_mv AT araujoantonio evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT tavaresnuno evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT fariaanaluisa evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT gomesrosa evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT mendoncajoanacarvalho evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT parentebarbara evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT capelaandreia evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT baratafernando evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal
AT macedoana evaluationofcurrentantiemetictherapyresponseinpatientsundergoingmecorhecregimensinportugal